SCHEDULE: Adage Capital Management Discloses 6.23% Stake in Monopar Therapeutics

Adage Capital Management, L.P. has reported beneficial ownership of 6.23% of Monopar Therapeutics' common stock, including shares issuable upon warrant exercise.

Summary

• Adage Capital Management, L.P. (ACM), through its investment vehicle Adage Capital Partners, L.P. (ACP), has filed a Schedule 13G, indicating beneficial ownership of 424,195 shares of Monopar Therapeutics Inc. common stock.
• This holding represents 6.23% of the company's outstanding common stock as of March 17, 2026.
• The reported shares include 115,000 shares of common stock issuable upon the exercise of warrants held by ACP.
• The filing is made by ACM, Robert Atchinson (individually and as managing member of related entities), and Phillip Gross (individually and as managing member of related entities).
• The reporting persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, indicating significant investor interest but lacking operational or financial performance details to assess the company's current health.

Positives

• Adage Capital Management's significant stake suggests confidence in Monopar Therapeutics' long-term prospects.
• The inclusion of shares issuable upon warrant exercise indicates a potential for increased ownership and commitment.

Negatives

• The filing does not contain specific financial performance data or operational updates, limiting the assessment of current business health.

Risks

• The filing does not explicitly detail any risks associated with Monopar Therapeutics' business operations or the investment itself.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from Monopar Therapeutics. The future outlook is implied by Adage Capital Management's investment and the potential exercise of warrants.

Management Comments

• The reporting persons certify that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

Industry Context

StockSavvy.ai notes that significant stake acquisitions by investment firms like Adage Capital Management often signal a belief in the target company's growth potential or undervaluation within its sector, particularly in the biotechnology and therapeutics industry where such filings are common indicators of institutional interest.

Stakeholder Impact

• Shareholders may view Adage Capital Management's increased stake as a positive signal of institutional confidence, potentially influencing share price.
• Management of Monopar Therapeutics will be aware of the significant ownership by Adage Capital Management, which could influence strategic decisions or board composition discussions.

Next Steps

• Adage Capital Management may continue to hold or potentially increase its stake in Monopar Therapeutics.
• The company's future performance will dictate the long-term implications of this ownership.

Key Dates

Recommendation

This filing indicates a significant institutional investment but lacks the operational and financial performance data necessary to make a strong buy or sell recommendation. A 'hold' is appropriate pending further information on Monopar Therapeutics' business progress and financial results.

Keywords

Monopar Therapeutics, Schedule 13G, Adage Capital Management, Beneficial Ownership, Common Stock, Warrants, Investment, SEC Filing